Abstract
Background
Cardiac resynchronization therapy (CRT) is an established treatment option for heart failure patients. However, the implementation of triple‐chamber pacemakers can be cost‐prohibitive. His‐Purkinje system pacing (HPSP) can also enable cardiac resynchronization, and it can be achieved with relatively inexpensive conventional pacemakers.
Hypothesis
This article aims to comparatively evaluate the cost of implanting devices in different CRT strategies to provide meaningful guidance for clinical decision‐making by electrophysiologists.
Methods
Data was collected on the prices, designed life, and price/designed life of multiple mainstream models of CRT‐P, CRT‐D, dual‐chamber pacemakers, and single‐chamber pacemakers that were sold in the Chinese market in 2022. The prices, designed lives, and price/designed life of different pacemaker models were then compared.
Results
The costs of CRT‐P and CRT‐D (13008.44 ± 2752.30 USD and 22043.36 ± 3676.25 USD) were significantly higher than those of conventional pacemakers (dual‐chamber: 11142.39 ± 4273.85 USD and single‐chamber: 5634.28 ± 2032.80 USD) (p < .05). Additionally, the price/designed life of conventional pacemakers (dual‐chamber: 839.63 ± 258.62 US dollar/year and single‐chamber: 435.86 ± 125.44 US dollar/year) was significantly better than that of CRT‐P and CRT‐D (1386.91 ± 266.73 and 2585.53 ± 520.27 US dollar/year, respectively) (p < .05).
Conclusion
Conduction system pacing (CSP)‐based CRT is more cost‐effective than BVP‐based CRT. Furthermore, CSP‐based CRT can achieve cardiac resynchronization with conventional pacemakers and may be a good option for HF patients who do not need defibrillation.
Keywords: biventricular pacing, cardiac resynchronization therapy, conduction system pacing, cost analysis, pacemakers
Price/designed life comparison of different types of pacemakers. (A) Comparison of the price/designed life of different types of pacemakers. (B) Comparison of the price/designed life of triple‐chamber pacemakers and conventional pacemakers (unit: USD/years). *<0.05, **<0.01. Triple‐chamber pacemakers include the CRT‐D and CRT‐P; conventional pacemakers include dual‐chamber and single‐chamber pacemakers.
1. INTRODUCTION
Cardiac resynchronization therapy (CRT) is considered an effective treatment for patients with congestive heart failure (CHF) and broad QRS duration, LBBB QRS morphology, and left ventricular ejection fraction (LVEF) ≤35%. 1 CRT based on conventional biventricular pacing (BVP) has been studied in many clinical trials, and it is associated with improved hospitalization and mortality rates among HF patients. 2 BVP can achieve cardiac electromechanical resynchronization and is the cornerstone of CRT.
Although BVP‐based CRT is widely accepted, the implant rate of CRT in heart failure (HF) patients who are indicated for CRT and successfully treated is very low. Lars and colleagues reported that only 21.4% of HF patients accepted CRT (841 patients accepted CRT among 3935 patients who were indicated for CRT) according to results from the Swedish Heart Failure Registry. 3 In addition to the technical difficulty of BVP‐based CRT operation, the high cost of triple‐chamber pacemakers is also an important factor that limits their application. Unfortunately, many economically disadvantaged patients have to give up reasonable treatment due to their inability to afford the high cost of CRT. In the end, they have to endure the suffering caused by heart failure, or even death.
Fortunately, the His‐Purkinje system pacing (HPSP) developed recently has been proven to achieve cardiac resynchronization. More importantly, it can achieve ventricular synchronous contraction by using conventional pacemakers (dual‐chamber or single‐chamber pacemakers). HPSP, also called conduction system pacing (CSP), includes His bundle pacing (HBP) and left bundle branch pacing (LBBP). CSP significantly shortens the QRS duration, improves the LVEF, and reduces the incidence of primary endpoints, resulting in improved clinical outcomes. 4 , 5 Both HBP and LBBP can successfully achieve CRT. 6 , 7 , 8
The devices used in BVP‐based CRT (Figure 1D) are triple‐chamber pacemakers, CRT‐pacemakers (CRT‐P), and CRT‐defibrillators (CRT‐D) (Figure 1A), and these devices are relatively expensive. However, HBP (Figure 1E) and LBBP (Figure 1F) can be used to achieve CRT with relatively inexpensive conventional dual‐chamber (Figure 1B) or single‐chamber pacemakers (Figure 1C).
Figure 1.
The devices, positions of pace leads in the heart, and ECGs of different CRT strategies. (A) Schematic diagram of a triple‐chamber pacemaker. (B) Schematic diagram of a dual‐chamber pacemaker. (C) Schematic diagram of a single‐chamber pacemaker. (D) Conventional CRT using BVP based on right ventricular pacing and coronary venous pacing. (E) HBP is the real physiological pacing modality that directly activates the conduction bundle. (F) LBBP can directly activate the native left bundle branch region. (G) The 12‐lead ECG after BVP; the paced QRS duration was 134 ± 15 ms. 9 (H) For the 12‐lead ECG after HBP, the paced QRS duration was 103.8 ± 13 ms. 10 (I) For the 12‐lead ECG after LBBP, the paced QRS duration was 114.1 ± 10.7 ms. 10 BVP, biventricular pacing; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; HBP, His bundle pacing; LBBP, left bundle branch pacing.
To date, there has been no study to directly compare the cost analysis of different CRT strategies. Therefore, we collected and analyzed data on the prices, designed lives, and price/designed life of mainstream models of CRT‐P, CRT‐D, dual‐chamber pacemakers, and single‐chamber pacemakers that were sold in the Chinese market. Then, we comparatively studied the cost analysis of different CRT strategies to provide meaningful guidance for decision‐making by electrophysiologists.
2. METHODS
We collected data on the prices, designed lives, and price/designed life of multiple mainstream models of CRT‐P, CRT‐D, dual‐chamber pacemakers, and single‐chamber pacemakers from Medtronic, Abbott, Boston Scientific, and Biotronik that were sold in the Chinese market in 2022 (Table 1). The prices of CRT‐P (n = 8), CRT‐D (n = 9), dual‐chamber pacemakers (n = 11), and single‐chamber pacemakers (n = 9) were converted from Chinese Yuan to US dollars at an exchange rate of 6.8171 on August 21, 2022. Then, we compared the prices, designed lives, and price/designed life of the different pacemaker models.
Table 1.
Comparison of different types of pacemakers.
| Corporation | Type | Category | Price (US dollar) | Design life (year) | Applicable procedure |
|---|---|---|---|---|---|
| Medtronic | C5TR01 | CRT‐P | 11 735 | 6~10 | BVP/LOT‐CRT/HOT‐CRT |
| Medtronic | C2TR01 | CRT‐P | 8215 | 6~10 | BVP/LOT‐CRT/HOT‐CRT |
| Medtronic | DTBC2QQ | CRT‐D | 18 336 | 6~12 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Medtronic | DTBA2QQ | CRT‐D | 24 204 | 6~12 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Medtronic | DTBA2D4 | CRT‐D | 23 104 | 6~12 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Medtronic | A3DR01 | Dual‐chamber | 8787 | 8~10 | HBP and LBBP |
| Medtronic | X3DR01 | Dual‐chamber | 13 187 | 15 | HBP and LBBP |
| Medtronic | SEDRL1 | Dual‐chamber | 6454 | 10~12 | HBP and LBBP |
| Medtronic | EN1SR01 | Single‐chamber | 6132 | 8~10 | HBP and LBBP |
| Medtronic | X3SR01 | Single‐chamber | 8772 | 15 | HBP and LBBP |
| Medtronic | SESR01 | Single‐chamber | 3503 | 8 | HBP and LBBP |
| Abbott | PM3262 | CRT‐P | 17 603 | 9 | BVP/LOT‐CRT/HOT‐CRT |
| Abbott | PM3160 | CRT‐P | 13 202 | 10 | BVP/LOT‐CRT/HOT‐CRT |
| Abbott | PM3242 | CRT‐P | 11 295 | 9 | BVP/LOT‐CRT/HOT‐CRT |
| Abbott | CD3371‐40Q | CRT‐D | 23 412 | 8 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Abbott | CD3371‐40 | CRT‐D | 26 111 | 8 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Abbott | CD3367‐40QC | CRT‐D | 17 603 | 10 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Abbott | PM2282 | Dual‐chamber | 20 537 | 15 | HBP and LBBP |
| Abbott | PM2182 | Dual‐chamber | 13 187 | 15 | HBP and LBBP |
| Abbott | PM2272 | Dual‐chamber | 16 136 | 14 | HBP and LBBP |
| Abbott | PM1182 | Single‐chamber | 8068 | 18 | HBP and LBBP |
| Abbott | PM1172 | Single‐chamber | 7334 | 18 | HBP and LBBP |
| Abbott | PM1124 | Single‐chamber | 4694 | 16 | HBP and LBBP |
| Boston Scientific | U128 | CRT‐P | 14 440 | 11 | BVP/LOT‐CRT/HOT‐CRT |
| Boston Scientific | G148 | CRT‐D | 16 480 | 8 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Boston Scientific | L131 | Dual‐chamber | 9182 | 15 | HBP and LBBP |
| Boston Scientific | S722 | Dual‐chamber | 8633 | 15 | HBP and LBBP |
| Boston Scientific | S701 | Single‐chamber | 3155 | 10 | HBP and LBBP |
| Biotronik | Edora 8HF‐T QP | CRT‐P | 14 522 | 10 | BVP/LOT‐CRT/HOT‐CRT |
| Biotronik | Edora 8HF‐T | CRT‐P | 13 055 | 10 | BVP/LOT‐CRT/HOT‐CRT |
| Biotronik | Rivacor 7 HF‐T QP | CRT‐D | 26 404 | 9 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Biotronik | Iforia7 HF‐T | CRT‐D | 22 737 | 7.5 | BVP/LOT‐CRT/HOT‐CRT and ICD |
| Biotronik | Edora 8 DR | Dual‐chamber | 11 002 | 12 | HBP and LBBP |
| Biotronik | Evia DR | Dual‐chamber | 7995 | 12 | HBP and LBBP |
| Biotronik | Estella DR | Dual‐chamber | 7467 | 12 | HBP and LBBP |
| Biotronik | Evia SR | Single‐chamber | 4283 | 12 | HBP and LBBP |
| Biotronik | Estella SR | Single‐chamber | 4767 | 12 | HBP and LBBP |
Abbreviations: BVP, biventricular pacing; CRT‐D, cardiac resynchronization therapy defibrillator; CRT‐P, cardiac resynchronization therapy pacemaker; HBP, His bundle pacing; HOT‐CRT, His‐optimized CRT; ICD, implantable cardioverter‐defibrillator; LBBP, left bundle branch pacing; LOT‐CRT, left bundle branch‐optimized CRT.
2.1. Statistical analysis
SPSS 26.0 was used for statistical analysis in this study. Measurement data are expressed as x ± s. Comparisons among multiple groups of independent samples were conducted in pairs. One‐way ANOVA was used for normally distributed data, and a nonparametric test was used for nonnormally distributed data. Two groups of independent samples were compared in pairs. Data with a normal distribution were analyzed by t test, and data with a nonnormal distribution were analyzed by nonparametric test. p < .05 was considered statistically significant.
3. RESULTS
3.1. Price of different pacemakers
The average price of mainstream models of CRT‐P, CRT‐D, dual‐chamber pacemakers, and single‐chamber pacemakers made by Medtronic, Abbott, Boston Scientific, and Biotronik and sold in the Chinese market were 13008.44 ± 2752.30 USD, 22043.36 ± 3676.25 USD, 11142.39 ± 4273.85 USD, and 5634.28 ± 2032.80 USD, respectively. The average price of CRT‐D > CRT‐P > dual‐chamber pacemakers > single‐chamber pacemakers. There were differences among the groups (p < .05). (Table 2 and Figure 2A) Triple‐chamber pacemakers were more expensive than conventional pacemakers, and the difference was statistically significant (p < .05) (Table 2 and Figure 2B).
Table 2.
Comparison of prices, designed lives, and price/designed life of different types of pacemakers.
| Projects | Triple‐chamber pacemakers | Conventional pacemakers | p Value | ||
|---|---|---|---|---|---|
| CRT‐P | CRT‐D | Dual‐chamber | Single‐chamber | ||
|
Price (US dollar) |
17791.63 ± 5628.44 | 8663.74 ± 4388.36 | .000 | ||
| 13008.44 ± 2752.30 | 22043.36 ± 3676.25 | 11142.39 ± 4273.85 | 5634.28 ± 2032.80 | .000 | |
|
Designed life (years) |
8.97 ± 0.98 | 13.15 ± 2.89 | .000 | ||
| 9.38 ± 1.06 | 8.61 ± 0.78 | 13.18 ± 2.09 | 13.11 ± 3.79 | .000 | |
| Price/designed life | 2021.47 ± 739.43 | 657.93 ± 290.35 | .000 | ||
| 1386.91 ± 266.73 | 2585.53 ± 520.27 | 839.63 ± 258.62 | 435.86 ± 125.44 | .000 | |
Note: One‐way analysis of variance (ANOVA) was used to compare the differences between the means of multiple independent samples. Two groups of independent samples were compared in pairs. Data with a normal distribution were analyzed by t test, and data with a nonnormal distribution were analyzed by nonparametric test. p < .05 was considered statistically significant.
Abbreviations: CRT‐D, cardiac resynchronization therapy‐defibrillator; CRT‐P, cardiac resynchronization therapy‐pacemaker.
Figure 2.
Price comparison of different types of pacemakers. (A) Comparison of the prices of different types of pacemakers (unit: USD). (B) Comparison of the prices of triple‐chamber pacemakers and conventional pacemakers (unit: USD). *<0.05, **<0.01. Triple‐chamber pacemakers include the CRT‐D and CRT‐P; conventional pacemakers include dual‐chamber and single‐chamber pacemakers. CRT‐D, cardiac resynchronization therapy‐ defibrillator; CRT‐P, cardiac resynchronization therapy‐pacemaker; NS, no statistical differences.
3.2. Designed lives of different pacemakers
The designed lives of the mainstream models of CRT‐P, CRT‐D, dual‐chamber pacemakers, and single‐chamber pacemakers made by Medtronic, Abbott, Boston Scientific, and Biotronik were 9.38 ± 1.06 years, 8.61 ± 0.78 years, 13.18 ± 2.09 years, and 13.11 ± 3.79 years, respectively. The designed life of dual‐chamber pacemakers > single‐chamber pacemakers > CRT‐P > CRT‐D. There were significant differences among the groups (p < .05). (Table 2 and Figure 3A) Comparing the designed life of triple‐chamber pacemakers with that of conventional pacemakers, triple‐chamber pacemakers had shorter lifespans, and the difference was statistically significant (p < .05) (Table 2 and Figure 3B).
Figure 3.
Designed life comparison of different types of pacemakers. (A) Comparison of the designed lives of different types of pacemakers (unit: years). (B) Comparison of the designed lives of triple‐chamber pacemakers and conventional pacemakers (unit: years). *<0.05, **<0.01. Triple‐chamber pacemakers include the CRT‐D and CRT‐P; conventional pacemakers include dual‐chamber and single‐chamber pacemakers. CRT‐D, cardiac resynchronization therapy‐ defibrillator; CRT‐P, cardiac resynchronization therapy‐pacemaker; NS, no statistical differences.
3.3. Price/designed life of different pacemakers
The price/designed life of the mainstream models of CRT‐P, CRT‐D, dual‐chamber pacemakers, and single‐chamber pacemakers made by Medtronic, Abbott, Boston Scientific, and Biotronik was 1386.91 ± 266.73, 2585.53 ± 520.27, 839.63 ± 258.62, and 435.86 ± 125.44 US dollars/year, respectively. The price/designed life of single‐chamber pacemakers > dual‐chamber pacemakers > CRT‐P > CRT‐D. There were significant differences among the groups (p < .05). (Table 2 and Figure 4A) Triple‐chamber pacemakers had lower cost performance than conventional pacemakers, and the difference was statistically significant (p < .05) (Table 2 and Figure 4B).
Figure 4.
Price/designed life comparison of different types of pacemakers. (A) Comparison of the price/designed life of different types of pacemakers. (B) Comparison of the price/designed life of triple‐chamber pacemakers and conventional pacemakers (unit: USD/years). *<0.05, **<0.01. Triple‐chamber pacemakers include the CRT‐D and CRT‐P; conventional pacemakers include dual‐chamber and single‐chamber pacemakers. CRT‐D, cardiac resynchronization therapy‐ defibrillator; CRT‐P, cardiac resynchronization therapy‐pacemaker.
The costs of CRT‐P and CRT‐D were significantly higher than those of conventional pacemakers (p < .05), and the price/designed life of conventional pacemakers was significantly better than that of CRT‐P and CRT‐D (p < .05).
4. DISCUSSION
In this study, we investigated the cost analysis of different CRT strategies. Our findings revealed that the CSP‐based CRT strategy, which only requires a dual‐chamber/single‐chamber pacemaker, has better price advantage in comparison to the BVP‐based CRT strategy, which requires a triple‐chamber pacemaker. These results provide valuable guidance for electrophysiologists in making clinical decisions, especially when patients requiring CRT have financial constraints.
Our analysis indicated that the costs of CRT‐D are higher than that of CRT‐P and dual‐chamber/single‐chamber pacemakers. Single‐chamber pacemakers emerged as the cheapest and most affordable device. This result is consistent with our clinical experience. BVP‐based CRT strategy requires a triple‐chamber pacemaker (CRT‐D/P) to achieve synchronous contraction of the ventricle. In contrast to BVP‐based CRT, either HBP or LBBP can achieve CRT by using conventional pacemakers (dual‐chamber/single‐chamber), which have obvious price advantages. In addition, BVP‐based CRT necessitates the use of three electrodes during implantation, including the expensive left ventricle electrode. In contrast, the 3830 electrode (Medtronic) or Solia S electrode (Biotronik) used in HBP or LBBP is relatively inexpensive. When the number and price difference of upper electrodes are considered, the cost of BVP is higher.
In terms of pacemaker function, CRT‐P abandoned the defibrillation function, while CRT‐D added this function, which is suitable for CRT patients with malignant arrhythmia or the risk of sudden cardiac death, as they have no alternative options. If a single‐chamber pacemaker can achieve CSP‐CRT, it is undoubtedly the most price advantage choice. Unfortunately, this strategy is not feasible for patients requiring atrioventricular synchronized pacing. Therefore, CSP‐CRT with a single‐chamber pacemaker is only suitable for a minority of patients with atrial fibrillation.
The cost of BVP is significantly higher than that of physiological pacemakers, and the designed lives of CRT‐P or CRT‐D (6–10 years) are generally shorter than those of conventional pacemakers (minimum of 10–15 years). The actual cost of conventional BVP is higher when medical costs of later replacements are considered. This is also consistent with our research findings.
Several current clinical CRT strategies have been shown to be effective for cardiac electromechanical resynchronization. 11 However, there is a significant difference in the prices of different CRT strategies. Our study found that different CRT strategies have varying levels of cost analysis, as represented by price to lifespan ratio. Conventional pacemakers were found to have better price advantage compared to CRT pacemakers.
BVP has been widely performed and well‐studied in clinical settings, and it is still recognized as the cornerstone for achieving CRT. However, BVP has certain disadvantages, such as stimulation of the diaphragm and high pacing threshold, and it can be affected by anatomical limitations and the condition of the target vessel, which limit its success rate. 12 Notably, 30%–50% of patients do not respond to BVP. 13 , 14 HBP is the most physiologically consistent method of ventricular pacing, and has been shown to improve the long‐term prognosis of HF patients. 6 , 15 , 16 It has some limitations, including high pacing threshold and perceptual abnormalities, and is not suitable for patients with block sites below the His bundle. LBBP has the advantages of simple operation, high success rate, stable parameters, and few complications. 17 , 18 HPSP may be a promising option for surgical operations and parameters when conventional methods are not feasible.
5. CONCLUSION
Compared with BVP‐based CRT, CSP‐based CRT is more cost effective. Additionally, CSP‐based CRT can achieve cardiac resynchronization with a conventional pacemaker and may be a good option for HF patients who do not need defibrillation, especially for patients who have experienced BVP‐based CRT failure or are unable to afford the price of BVP.
6. LIMITATIONS
Only some, not all, pacemaker models were included in this study, and the results may be somewhat biased. In addition, pacemaker prices are influenced by local health care policies.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
We would like to thank Mr. Jiuzhou Duan and Shenhao Wang for their help and contribution in data collection.
Chen M, Shi J, Zhang Y, et al. Comparative cost analysis of implanting devices in different cardiac resynchronization therapeutic strategies. Clin Cardiol. 2023;46:1227‐1233. 10.1002/clc.24107
Contributor Information
Yongquan Wu, Email: wuyongquan67@163.com.
Junmeng Zhang, Email: drjmzh@outlook.com.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request. The data sets used or analyzed during the current study are available from the corresponding author on reasonable request.
REFERENCES
- 1. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427‐3520. [DOI] [PubMed] [Google Scholar]
- 2. Upadhyay GA, Tung R. Keeping pace with the competition: His bundle versus biventricular pacing in heart failure. Curr Opin Cardiol. 2020;35(3):295‐307. [DOI] [PubMed] [Google Scholar]
- 3. Lund LH, Braunschweig F, Benson L, Ståhlberg M, Dahlström U, Linde C. Association between demographic, organizational, clinical, and socio‐economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. Eur J Heart Fail. 2017;19(10):1270‐1279. [DOI] [PubMed] [Google Scholar]
- 4. Vijayaraman P, Zalavadia D, Haseeb A, et al. Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. Heart Rhythm. 2022;19(8):1263‐1271. [DOI] [PubMed] [Google Scholar]
- 5. Gui Y, Ye L, Wu L, Mai H, Yan Q, Wang L. Clinical outcomes associated with His‐Purkinje system pacing vs. biventricular pacing, in cardiac resynchronization therapy: a meta‐analysis. Front Cardiovasc Med. 2022;9:707148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Huang W, Su L, Wu S, et al. Long‐term outcomes of His bundle pacing in patients with heart failure with left bundle branch block. Heart. 2019;105(2):137‐143. [DOI] [PubMed] [Google Scholar]
- 7. Vijayaraman P, Ponnusamy S, Cano Ó, et al. Left bundle branch area pacing for cardiac resynchronization therapy. JACC Clin Electrophysiol. 2021;7(2):135‐147. [DOI] [PubMed] [Google Scholar]
- 8. Zu L, Wang Z, Hang F, et al. Cardiac resynchronization performed by LBBaP‐CRT in patients with cardiac insufficiency and left bundle branch block. Ann Noninvasive Electrocardiol. 2021;26(6):e12898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Vinther M, Risum N, Svendsen JH, Møgelvang R, Philbert BT. A randomized trial of his pacing versus biventricular pacing in symptomatic HF patients with left bundle branch block (His‐Alternative). JACC Clin Electrophysiol. 2021;7(11):1422‐1432. [DOI] [PubMed] [Google Scholar]
- 10. Wu S, Cai M, Zheng R, et al. Impact of QRS morphology on response to conduction system pacing after atrioventricular junction ablation. ESC Heart Failure. 2021;8(2):1195‐1203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wang Z, Wu Y, Zhang J. Cardiac resynchronization therapy in heart failure patients: tough road but clear future. Heart Fail Rev. 2021;26(3):735‐745. [DOI] [PubMed] [Google Scholar]
- 12. Chen M, Dong Z, Zhang Y, Liu J, Zhang J. A conversion CRT strategy combined with AVJA may be a perspective alternative for heart failure patients with persistent atrial fibrillation. Heart Fail Rev. 2023;28(2):367‐377. [DOI] [PubMed] [Google Scholar]
- 13. Yu CM, Bleeker GB, Fung JWH, et al. Left ventricular reverse remodeling but not clinical improvement predicts long‐term survival after cardiac resynchronization therapy. Circulation. 2005;112(11):1580‐1586. [DOI] [PubMed] [Google Scholar]
- 14. Sieniewicz BJ, Gould J, Porter B, et al. Understanding non‐response to cardiac resynchronisation therapy: common problems and potential solutions. Heart Fail Rev. 2019;24(1):41‐54. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Lustgarten DL, Crespo EM, Arkhipova‐Jenkins I, et al. His‐bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: a crossover design comparison. Heart Rhythm. 2015;12(7):1548‐1557. [DOI] [PubMed] [Google Scholar]
- 16. Sharma PS, Naperkowski A, Bauch TD, et al. Permanent His bundle pacing for cardiac resynchronization therapy in patients with heart failure and right bundle branch block. Circ: Arrhythmia Electrophysiol. 2018;11(9):e006613. [DOI] [PubMed] [Google Scholar]
- 17. Wang Y, Zhu H, Hou X, et al. Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy. J Am Coll Cardiol. 2022;80(13):1205‐1216. [DOI] [PubMed] [Google Scholar]
- 18. Zhang J, Zhang Y, Sun Y, Chen M, Wang Z, Ma C. Success rates, challenges and troubleshooting of left bundle branch area pacing as a cardiac resynchronization therapy for treating patients with heart failure. Front Cardiovasc Med. 2023;9:1062372. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request. The data sets used or analyzed during the current study are available from the corresponding author on reasonable request.